Pfizer and BioNTech apply to the European Medicines Agency for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for the 2023-2024 fall and winter season, according to statement.
- Expect to be ready to ship the adapted vaccines to EU member states immediately following regulatory approval
- Application in the US expected to follow in the coming days
To view the source of this information, click
To contact the reporter on this story:
To contact the editors responsible for this story:
Alexey Anishchuk
© 2023 Bloomberg L.P. All rights reserved. Used with permission. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.